In Brief: Glaxo Wellcome Retrovir
Executive Summary
Glaxo Wellcome Retrovir: 300 mg tablet formulation of zidovudine launched the week of Oct. 21. The 300 mg tablet, approved Oct. 4 by FDA, is intended to simplify combination with Glaxo's Epivir (3TC, lamivudine) to allow for twice-daily dosing of 150 mg Epivir plus 300 mg Retrovir; previously, patients took Epivir twice daily but two 100 mg Retrovir capsules three times daily. A dose frequency study found no safety or efficacy differences between the formulations, according to labeling. Price to wholesalers will be $3.98 per tablet for 300 mg form; 100 mg tabs cost $1.59 each AWP...